Magazine
Sign up for your free subscription and keep up-to-date.
Upcoming Events
Newsletters
Stay updated on the latest news and technologies with Bioscienceworld's newsletters.
Five to choose from.
Patents
|
July 26 2007
Urodynamix files for patents Urodynamix Technologies Ltd. has filed a series of applications with the United States Patent and Trademark Office for inventions related to medical applications of near-infrared spectroscopy, the core technology behind the company's URO-NIRS platform.
|
|
June 14 2007
Allon granted US patent for composition of matter Allon Therapeutics announces that it has been granted a US patent covering additional composition of matter for the products in the ADNP platform, which broadens the intellectual property of Allon's patent portfolio.
|
|
June 01 2007
Queen's-developed decontamination system for chemical warfare agents issued U.S. patent A non-toxic method for decomposing chemical warfare agents discovered at Queen's University has been issued a U.S. patent. The patent was issued under number 7,214,836 on May 8, 2007 and is classified as a Method for Decomposing Organophosphorus Compounds.
|
|
April 23 2007
Patents broadly protect core technology behind chemokine-based therapeutic platform Osprey Pharmaceuticals Limited announces that it has been granted three patents by the U.S. Patent Office. The patents protect the use of conjugated chemokines to selectively and systematically eliminate overactive leukocytes implicated in most chronic diseases, the core technology behind Osprey's Leukocyte Population Modulator (LPM) platform.
|
|
February 12 2007
Axela Biosensors Inc. to license patented technology Axela Biosensors Inc. and Beckman Coulter Inc announces the signing of a nonexclusive licensing agreement, giving Axela rights to Beckman Coulter's patented A(2)(R) Universal Linker Capture Technology. The terms of the license were not disclosed.
|
|
February 12 2007
Isotechnika receives European patent for lead immunosuppressive drug Isotechnika Inc. announces that the company has been issued European Patent No. EP0991660 for its lead immunosuppressive drug, ISA247.
|
|
November 27 2006
University of Texas Grants License The University of Texas Southwestern Medical Center at Dallas has granted Covalon Technologies Ltd. a non-exclusive license for technology covered by a U.S. patent entitled "Endothelial PAS Domain Protein" (EPAS1).
|
|
November 02 2006
PainCeptor Pharma Corp. Receives Four Patents PainCeptor Pharma Corp. (Montreal, QC) received four patents for two of its drug development programs.
|
|
November 02 2006
YM BioSciences Clears US Cuban Import Restriction The U.S. Treasury Department's Office of Foreign Assets Control (OFAC) has approved a license allowing a U.S. subsidiary of YM BioSciences Inc. to import nimotuzumab from Cuba for the purpose of clinical trials in pediatric patients with pontine glioma.
|
|
October 02 2006
Allon granted Australian patent for new learning and memory compound Allon Therapeutics is continuing to develop unique compounds and related technology to treat the causes of more than nine brain diseases and conditions, including Alzheimers disease and mild cognitive impairment (MCI).
|
|
September 29 2006
Wex Pharmaceuticals Inc. Has Received Two Patents Wex Pharmaceuticals Inc. has received two patents, one from China and the other from the Ukraine.
|
|
July 05 2006
Stem Cell Therapeutics Inc. Receives Patent Stem Cell Therapeutics Inc., a subsidiary of Calgary-based Stem Cell Therapeutics Corp., has received a patent from the U.S. Patent and Trademark Office for combined regulation of neural cell production.
|
|
April 18 2006
Inovio Biomedical Granted Two New Patents Inovio Biomedical Corp. (San Diego, CA) has been granted two new patents -"Method for Muscle Delivery of Drugs, Nucleic Acids and Other Compounds," and "Enhanced Delivery of Naked DNA to Skin by Non-Invasive In Vivo Electroporation" - relating to the use of electroporation to deliver therapeutic agents.
|
|
February 06 2006
ASKED & ANSWERED Compiled by Amber Lepage-Monette Many academic institutions and some biotechnology companies develop new research tools during the course of their R&D programs.
|
|
January 01 2006
iCo Therapeutics Creates Strategic Team Vancover, B.C.-based iCo Therapeutics Inc. has created a Strategic Advisory Team that will assist management and the board of directors manage the company's growth and development.
|
|
September 13 2005
Asked & Answered Compiled by Amber Lepage-Monette This month's question was provided by students from the MBA program at the University of Alberta (Edmonton, AB).
How significant is the gap between university funding of discovery and applied research? How can this gap be bridged to focus a greater portion of research to the development of prototypes and other applications of new discoveries? |
|
June 14 2005
Post-marketing Observational Studies by John Sampalis, PhD Providing insight into real-life clinical practice regarding safety, efficacy and patients' drug compliance.
|
|
May 10 2005
Asked & Answered Compiled by Amber Lepage-Monette The following question was provided by students from the MBA program at the University of Alberta (Edmonton, AB).
In academia there is a recognized mantra: "publish or perish." However, in the development of IP, the mantra is "publish and perish" since publishing severely impairs one's ability to patent. |
|
March 07 2005
Cost-saving Patent Strategies for Small and New Companies By Jennifer Jannuska and Lenni Carreiro The pressure to get patents has never been greater for small and new companies. Patents are the hard currency of research-based businesses. Investors want to see them, competitors have them and companies need them - for licensing, leveraging, litigating and (occasionally) liquidating.
|
|
November 12 2004
Asked & Answered Compiled by Amber Lepage-Monette Over the past decade there has been a dramatic increase in expenditures to obtain and enforce patents for pharmaceutical applications. Cases exist where local and foreign governments have disregarded patent laws to allow for the delivery of pharmaceutical/medical services at an affordable price.
|
|
November 07 2004
Ecopia BioSciences Receives Patent for its Decipher® Technology St-Laurent, Que.-based Ecopia BioSciences Inc. has received a patent on its Decipher® technology from the Canadian Patent Office.
|
|
September 20 2004
ASKED & ANSWERED Compiled by Amber Lepage-Monette Among the major developed countries, significant uncertainty characterizes Canadian patent law with respect to living organisms.
|
|
May 14 2004
Asked & Answered Compiled by Amber Lepage-Monette Understanding firm performance is important to strategy development and firm operations.
|
|
February 16 2004
ASKED & ANSWERED Compiled by Amber Lepage-Monette THIS ISSUE'S ASKED & ANSWERED QUESTION WAS PROVIDED BY THE MEMBERS OF THE BIOPHARMA STUDENT GROUP IN THE QUEENS UNIVERSITY (KINGSTON, ON) MBA FOR SCIENCE & TECHNOLOGY PROGRAM AND THE PROGRAM DIRECTOR JEFF McGILL, PhD.
|
|
September 01 2003
Intellectual Property Disputes BY ANDREW M. SHAUGHNESSY AND CONOR D.M. MCCOURT Consider this: you are the business development manager of a small biotech company with responsibility for commercializing your company's technology. Your breakthrough product has recently emerged from successful Phase III clinical trials and has been protected since its infancy with patent applications across the world.
|
|
January 02 2003
Is Your Patent Portfolio Ready for Due Diligence? By Micheline Gravelle Like death and taxes, due diligence on a biotechnology company's patent portfolio is a certainty. Few biotechnology companies can bring a product to market without receiving venture capital and/or partnering with a larger company.
|